Hepatocellular carcinoma combined with portal vein cancer thrombus is often seen in clinical work, and portal hypertension caused by cancer thrombus obstructing the portal vein often leads to upper gastrointestinal hemorrhage, thus causing fatal risk. This is a very difficult problem encountered by clinicians. Currently, the district hospital has solved this problem through percutaneous hepatic penetration portal stent placement. 56-year-old Huang successfully received this treatment in our interventional ward and was discharged from the hospital, becoming another beneficiary of this advanced technology. The patient, Huang, male, 56 years old, had a history of hepatitis B for many years. In October 2011, he underwent CT examination for upper abdominal discomfort, suggesting hepatocellular carcinoma. According to the patient’s condition and physical status, he was no longer suitable for surgical treatment, so he was transferred from hepatobiliary surgery to interventional department on October 14, 2011, and he underwent hepatic artery and superior mesenteric artery angiography + perfusion chemoembolization on October 27, 2011, which showed filling defect of hepatic portal vein and confirmed the existence of large portal vein cancer thrombus, which had blocked more than 90% of the main portal vein. After repeatedly studying the CT and DSA results, the chief of our department and the doctor in charge decided to perform percutaneous hepatic portal vein stenting and actively made preoperative preparations, contacted the catheterization laboratory and ultrasound room, and everything was ready for the operation on November 4. During the operation, the hepatic portal vein was punctured smoothly, and the stent was released precisely, and the operation achieved immediate results. The patient recovered well after the operation and was relieved of the risk of upper gastrointestinal bleeding due to the increased portal pressure caused by portal vein cancer embolism, while improving the blood supply to the liver and creating conditions for subsequent chemoembolization treatment. Liver cancer is one of the tumors with high incidence in China, and the incidence of liver cancer combined with portal vein cancer embolism accounts for about 66.2% – 90.2%. Portal vein cancer embolism is an important factor leading to the dissemination and metastasis of tumor cells in the liver and affecting patients’ quality of life. With the development of portal vein cancer embolism, the most serious complication is the elevation of portal pressure, which leads to upper gastrointestinal bleeding and threatens patients’ lives. For portal vein cancer embolism, there is still a lack of effective and safe means. Interventional treatment has been widely used in clinical practice for its advantages of minimally invasive and reproducibility, and has achieved certain efficacy. At present, the main applied interventional treatment methods include transcatheter arterial infusion chemotherapy, transcatheter arterial chemoembolization, dual route chemoembolization of hepatic artery and portal vein, anhydrous alcohol injection and portal vein stent placement, and the combined treatment of multiple methods has achieved better efficacy. Among them, portal vein stent placement, on the basis of percutaneous hepatic penetration of portal vein for stent placement within the main trunk of portal vein, so that the occluded trunk is reopened, which can significantly reduce the portal vein pressure, and simultaneously feasible variceal vein embolization, which is conducive to the improvement of esophagogastric fundic varices and ascites; improve the portal vein blood supply of normal liver tissue, improve liver function, increase liver function storage, reduce liver failure, hepatic encephalopathy and upper gastrointestinal bleeding, which is conducive to further chemoembolization and other treatments for better tumor control. Not only can it improve the patient’s symptoms such as intractable ascites and upper gastrointestinal bleeding in the short term, but in the long term, because of the improvement of stent manufacturing technology and the use of overlapping stents, the stent restenosis rate is low, laying the foundation for the subsequent comprehensive treatment of patients with liver cancer and improving their prognosis. In recent years, with the in-depth research on the formation mechanism of portal vein cancer thrombosis, the interventional treatment of hepatocellular carcinoma combined with portal vein cancer thrombosis has become more aggressive and has achieved certain efficacy. Since the development of liver cancer interventional treatment, the interventional department of our hospital has been expanding new techniques of liver cancer interventional treatment and has formed a comprehensive treatment plan of liver cancer combining multiple interventional treatment modalities with its own characteristics, such as combining arterial chemoembolization with anhydrous alcohol injection ablation, combining arterial chemoembolization with precise radiotherapy, combining arterial chemoembolization with radioactive particle implantation, and combining arterial chemoembolization with radioactive particle implantation, and combining arterial chemoembolization with radioactive particle implantation. venous cancer embolism or edema of scrotum and lower extremities caused by pressure, portal vein stent placement for liver cancer and portal vein cancer embolism, arterial chemoembolization for liver cancer bone metastasis or brain metastasis, etc., so that the comprehensive interventional treatment level of liver cancer in our hospital has reached the advanced level in China.